RBC Capital lowered the firm’s price target on Thermo Fisher (TMO) to $651 from $694 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results in the Life Science Tools and Diagnostics sector. The firm anticipates another optimistic tone from the sector’s management teams while also updating its models to reflect a “more realistic” outlook on where FY25 guidance for most of these companies should go in light of NIH grant funding cuts, tariffs, and a pending trade war with China that is already having an impact, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Honeywell elects Stephen Williamson to board of directors
- Kroger, Thermo Fisher, AST SpaceMobile, Southern Co, and Prospect Capital: Insider Moves Revealed!
- Thermo Fisher price target lowered to $570 from $650 at Citi
- Strategic Acquisition Boosts Thermo Fisher’s Bioprocessing Position: Analyst Recommends Buy
- Thermo Fisher’s Strategic Acquisition of Solventum: A Path to Growth and Synergy
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue